MedTrace Logo

A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults

NCT00968669 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 329

Last updated 2014-06-04

Study results available
· View outcomes & findings →

Summary

To study the effectiveness and safety of multiple-doses of MEDI-528 on asthma control in adult participants with uncontrolled, moderate-to-severe, persistent asthma.

Conditions

Interventions

BIOLOGICAL

MEDI528 30 mg

MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks

BIOLOGICAL

MEDI528 100 mg

MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks

BIOLOGICAL

MEDI528 300 mg

MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks

OTHER

Placebo

Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Chad Oh, M.D. · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-11-30
Completion
2012-01-31

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • Colombia
  • Costa Rica
  • Panama
  • Peru
  • Philippines
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00968669 on ClinicalTrials.gov